GO
Loading...

Forest Laboratories Inc

More

  • Early Movers: RAD, HPQ, MU, FDX, WMT & More Thursday, 20 Jun 2013 | 8:03 AM ET

    Check out which companies are making headlines before the bell on Thursday:

  • Forest Labs Braces for Third Bout With Icahn Friday, 7 Jun 2013 | 7:39 AM ET
    Carl Icahn

    Forest Laboratories is trying to avert yet another bitter proxy battle with billionaire investor Carl Icahn ahead of its annual investor meeting this summer, sources said.

  • Early Movers: DD, TRV, UTX & More Tuesday, 23 Apr 2013 | 8:13 AM ET

    Some of the names on the move ahead of the open.

  • A Make-or-Break Week Ahead for the Stock Market Saturday, 20 Apr 2013 | 12:30 AM ET

    It's make-or-break time for the first-quarter earnings season, and it comes just as the stock market is showing signs of strain.

  • Early Movers: KO, GS, JNJ & More Tuesday, 16 Apr 2013 | 8:11 AM ET

    Some of the names on the move ahead of the open.

  • Early Movers: LEN, FRX, LULU & More Tuesday, 15 Jan 2013 | 7:51 AM ET

    Some of the names on the move ahead of the open.

  • Stocks Looking Beyond Debt Ceiling, for Now Monday, 14 Jan 2013 | 8:58 PM ET

    Stocks are so far looking past the brewing congressional debt ceiling drama but that could change quickly if it becomes very contentious.

  • Cramer makes the call on viewer favorites.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. *Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.

  • *Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.

  • Forest Labs 2Q profit down, cuts year forecasts Tuesday, 16 Oct 2012 | 11:40 AM ET

    NEW YORK-- Forest Laboratories Inc. again cut its annual net income guidance and lowered its sales estimates Tuesday, citing lower sales of its Alzheimer's disease drug Namenda and other products along with greater expenses and higher taxes. Shares of Forest declined 91 cents, or 2.5 percent, to $35.69 in morning trading.

  • Ironwood Pharma posts 3Q profit on drug approval Tuesday, 16 Oct 2012 | 12:06 AM ET

    CAMBRIDGE, Mass.-- Ironwood Pharmaceuticals Inc. said Tuesday it turned a profit in the third quarter after the Food and Drug Administration approved its irritable bowel syndrome treatment Linzess.

  • Stocks to Watch: C, PG, GSK & More Monday, 16 Jul 2012 | 8:21 AM ET

    Take a look at some of Monday’s morning movers:

  • Stocks to Watch: JPM, FRX, MLM & More Friday, 13 Jul 2012 | 7:58 AM ET

    Take a look at some of Friday’s morning movers:

  • Stocks to Watch: BCS, MSFT, CHK & More Tuesday, 3 Jul 2012 | 8:17 AM ET

    Take a look at some of Tuesday’s morning movers:

  • Carl Icahn is no stranger to conflict and controversy. But this time, his rhetoric isn’t only scathing, it’s also rather serious.

  • Investor Carl Icahn updates "Fast Money" on what he wants to see happen to a company he calls a "very undervalued asset."

  • Icahn Takes Aim at Forest Labs     Monday, 2 Jul 2012 | 5:11 PM ET

    Billionaire investor Carl Icahn questioned the timing of certain stock sales by Forest Laboratories' CEO Howard Soloman today, and discusses his concerns over its corporate governance.

  • Despite the flurry of debate surrounding ObamaCare, which the U.S. Supreme Court is set to rule on later this week, two managing directors emphasized the new products that will be emerging from pharmaceutical companies’ pipelines soon.